Pfizer Ltd. posts Q1 FY25 PAT at Rs. 150.71 Cr
Pfizer Ltd. has reported total income of Rs. 604.70 crores during the period ended June 30, 2024
Pfizer Ltd. has reported total income of Rs. 604.70 crores during the period ended June 30, 2024
MKP11093 has shown strong results in preclinical studies with a promising safety and selectivity profile
The cGMP-4 facility will further strengthen the company's ability to serve global partners
The facility has been designed with a dual focus on efficiency and sustainability
Teva received Fast Track designation from the U.S. Food and Drug Administration for emrusolmin (TEV-56286), an investigational treatment for Multiple System Atrophy (MSA) in Phase 2 development
The company has received approval from DCGI to begin patient enrolment and dosing in the country
PendraCare Group develops, manufactures and sells innovative cardiology catheter solutions and provides design, development and manufacturing services to other global OEM’s
Under the terms of this agreement, Synthon will be responsible for obtaining final regulatory approval for its Ozanimod Capsules product
First Indian company to follow global recommendations in accordance with the World Health Organisation (WHO)
Generic Saxenda is the first-ever generic GLP-1 indicated for weight loss, addressing increased demand for this category of therapies in the US market
Subscribe To Our Newsletter & Stay Updated